Navigation Links
Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations
Date:3/17/2010

INDIANAPOLIS, March 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today issued a statement and details regarding the stolen company products from its distribution operations in Enfield, Connecticut on Sunday, March 14.  

Lilly is working with the U.S. Food and Drug Administration's Office of Criminal Investigations (FDA), and other law enforcement officials, to recover cases of select lots of pharmaceutical products that were stolen from one of Lilly's United States distribution centers located in Enfield, Connecticut, on Sunday, March 14, 2010.  A list of products stolen from the facility can be found at the bottom of this press release.

"Since early Sunday morning, Lilly has taken quick and appropriate actions to ensure the safety of our medicines," said Dr. Fionnuala M. Walsh, Lilly's senior vice president of global quality.  "The U.S. pharmaceutical distribution system is tightly controlled and monitored, making it extremely difficult for stolen product to make it to patients through legitimate channels. However, we will continue to work closely with local and federal law enforcement authorities, the FDA, and our distribution partners to maintain the integrity of our drug supply chain."

Product from the affected lots which had been delivered from Lilly to retailers, wholesalers or institutions prior to March 14 was approved for its intended use and is not affected by this event.  Product containing these lot numbers has been distributed by Lilly within the United States, Puerto Rico and its territories.

These medicines require a prescription for purchase.  Consumers should purchase Lilly products only from well-established and reputable retailers.  Lilly recommends that consumers always inspect the product and label for signs of tampering before opening.  

Lilly is advising practitioners, retailers and consumers to check all pharmaceutical products for signs of tampering or damage prior to purchase and/or use.  Pharmacists and other health care professionals should not use the product if it has been removed from the sealed bottle or container, if the induction seal has been compromised, or in the case of glass vials, if the flip cap appears to have been disturbed in any way.  

To assist the FDA and the law enforcement agencies in their investigation, Lilly stopped distributing product with the affected lot numbers on Monday, March 15, 2010.

Lilly is asking for the public's help in reporting any information regarding the stolen products to FDA's Office of Criminal Investigations (OCI) by calling (800) 551-3989 or by visiting the OCI website www.fda.gov/OCI.

For medical or other related inquiries about this matter, contact Lilly at 1-800-LILLYRX (1-800-545-5979).

Impacted Products

    
    
                              National Drug Code
    Product Description       (NDC)               Lot Number   Expiry Date
    -------------------       ------------------  ----------   -----------
    ALIMTA FINJ 500MG X1
     lyophilizedVIAL AM       00002-7623-01       A671076C      8/31/2011
    --------------------      -------------       --------      ---------
    CYMBALTA CAP 30MG X 30
     BTL AM                   00002-3240-30       A643056A      5/31/2012
    ----------------------    -------------       --------      ---------
    CYMBALTA CAP 30MG X 30
     BTL AM                   00002-3240-30       A662278C      7/31/2012
    ----------------------    -------------       --------      ---------
    CYMBALTA CAP 30MG X 30
     BTL AM                   00002-3240-30       A662281A      7/31/2012
    ----------------------    -------------       --------      ---------
    CYMBALTA CAP 60MG X30BOTL
     AM                       00002-3270-30       A672999A      9/30/2011
    ------------------------- -------------       --------      ---------
    CYMBALTA CAP 60MG
     X1000BOTL AM             00002-3270-04       A685790A     10/31/2011
    -----------------         -------------       --------     ----------
    EFFIENT TAB 10MG X30BOTL
     AM                       00002-4759-30       A650259A     12/31/2010
    ------------------------  -------------       --------     ----------
    GEMZAR 200MG VIALS        00002-7501-01       A670185A      8/31/2011
    ------------------        -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A668160D      8/31/2011
    -------------------       -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A670177A      9/30/2011
    -------------------       -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A670180A      8/31/2011
    -------------------       -------------       --------      ---------
    GEMZAR 1 GRAM VIALS       00002-7502-01       A670182A      9/30/2011
    -------------------       -------------       --------      ---------
    PROZAC PULV 20MG X 30
     BOTL DP                  00777-3105-30       A599046D      1/31/2012
    ---------------------     -------------       --------      ---------
    PROZAC PULV 20MG X 30
     BOTL DP                  00777-3105-30       A689619D     10/31/2012
    ---------------------     -------------       --------     ----------
    PROZAC PULV 40MG X 30
     BOTL DP                  00777-3107-30       A602567A      1/31/2012
    ---------------------     -------------       --------      ---------
    STRATTERA CAP 10MG X 30
     BOTL AM                  00002-3227-30       A621189A      3/31/2012
    -----------------------   -------------       --------      ---------
    STRATTERA CAP 25MG X 30
     BOTL AM                  00002-3228-30       A678353A      2/29/2012
    -----------------------   -------------       --------      ---------
    STRATTERA CAP 60MG X 30
     BOTL AM                  00002-3239-30       A621202A      3/31/2012
    -----------------------   -------------       --------      ---------
    STRATTERA CAP 100MG
     X30BOTL AM               00002-3251-30       A621205C      3/31/2012
    -------------------       -------------       --------      ---------
    SYMBYAX CAP 6/25MG X 30
     BOTL AM                  00002-3231-30       A562684A     10/31/2011
    -----------------------   -------------       --------     ----------
    ZYPREXA TAB 2.5MG X30BOTL
     AM                       00002-4112-30       A644710A      5/31/2011
    ------------------------- -------------       --------      ---------
    ZYPREXA TAB 5MG X30BOTL
     AM                       00002-4115-30       A668322A      8/31/2011
    -----------------------   -------------       --------      ---------
    ZYPREXA TAB 7.5MG X30BOTL
     AM                       00002-4116-30       A646193A      5/31/2011
    ------------------------- -------------       --------      ---------
    ZYPREXA TAB 10MG X30BOTL
     AM                       00002-4117-30       A641350C      5/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB 10MG X30BOTL
     AM                       00002-4117-30       A668323A      8/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB 15MG X 1000
     BOTL AM                  00002-4415-04       A647860A      5/31/2012
    -----------------------   -------------       --------      ---------
    ZYPREXA TAB 15MG X30BOTL
     AM                       00002-4415-30       A690238A     10/31/2012
    ------------------------  -------------       --------     ----------
    ZYPREXA TAB 20MG X30BOTL
     AM                       00002-4420-30       A677956A      8/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB 20MG X30BOTL
     AM                       00002-4420-30       A677958C      8/31/2012
    ------------------------  -------------       --------      ---------
    ZYPREXA TAB ID100 10MG
     XID100BLCD AM            00002-4117-33       A632252D      4/30/2012
    ----------------------    -------------       --------      ---------
    ZYPREXA ZYDIS TAB 5MG X
     30 SACH AM               00002-4453-85       976041A        7/1/2012
    -----------------------   -------------       -------        --------
    ZYPREXA ZYDIS TAB 10MG X
     30 SACH AM               00002-4454-85       971159A        7/1/2012
    ------------------------  -------------       -------        --------
    ZYPREXA ZYDIS TAB 20MG X
     30 SACH AM               00002-4456-85       963999A        5/1/2012
    ------------------------  -------------       -------        --------
    
    

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

Alimta® (pemetrexed disodium)

Cymbalta® (duloxetine hydrochloride)

Effient™ (prasugrel)

Gemzar® (gemcitabine hydrochloride)

Prozac® (fluoxetine hydrochloride)

Strattera® (atomoxetine hydrochloride)

Symbyax (olanzapine / fluoxetine hydrochloride)

Zyprexa® (olanzapine)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company

Back to top
'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Statement: ACCORD Lipid Results Support Treatment Guidelines for Fibrate Use
2. Pew Statement on Congressional Hearing Regarding FDA Drug Safety Reforms
3. SCAI Statement on the CREST Study Findings: Carotid Stenting is as Safe and Effective as Carotid Surgery in Patients at Risk for Stroke
4. GSK Statement on FDAs Proposed Label Revisions for Some Asthma Medicines
5. SCAI Statement on the Hospitalization of Former President Bill Clinton
6. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
7. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Viral Genetics Files 2009 3rd Quarter Consolidated Financials and Information Statement at Pinksheets.com
9. Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse
10. Sinovac Files Shelf Registration Statement
11. Derma Sciences Files S-1 Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):